"Epirubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
| Descriptor ID |
D015251
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175.200 D04.615.562.050.200.175.200 D09.408.051.059.200.175.200
|
| Concept/Terms |
Epirubicin- Epirubicin
- 4'-Epidoxorubicin
- 4' Epidoxorubicin
- 4'-Epi-Doxorubicin
- 4' Epi Doxorubicin
- 4'-Epi-Adriamycin
- 4' Epi Adriamycin
- 4'-Epiadriamycin
- 4' Epiadriamycin
- 4'-Epi-DXR
- 4' Epi DXR
Ellence- Ellence
- Pharmorubicin
- Farmorubicine
- Farmorubicin
|
Below are MeSH descriptors whose meaning is more general than "Epirubicin".
Below are MeSH descriptors whose meaning is more specific than "Epirubicin".
This graph shows the total number of publications written about "Epirubicin" by people in this website by year, and whether "Epirubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epirubicin" by people in Profiles.
-
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240.
-
An Organoid-Based Preclinical Model of Human Gastric Cancer. Cell Mol Gastroenterol Hepatol. 2019; 7(1):161-184.
-
An integrative approach identified genes associated with drug response in gastric cancer. Carcinogenesis. 2015 Apr; 36(4):441-51.
-
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015 Feb; 150(1):169-80.
-
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer. 2015 Feb 17; 112(4):630-5.
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
-
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol. 2013 Apr; 24(4):909-16.
-
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011 Apr 20; 29(12):1578-86.
-
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl). 2011 Jan; 124(2):199-204.
-
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96.